长春瑞滨单药与联合铂类一线治疗老年晚期非小细胞肺癌临床观察

目的观察长春瑞滨单药和长春瑞滨联合顺铂一线治疗老年晚期非小细胞肺癌的疗效和毒性反应。方法 44例晚期非小细胞肺癌,其中21例予长春瑞滨25mg/m2,第1.8天给药,每21天为1周期,23例予长春瑞滨联合顺铂,长春瑞滨25mg/m2,第1,8天,顺铂25mg/m2第1～3天,随访至进展后患者死亡。结果单药组CR、PR、SD、PD、总有效率,1年生存率分别为0%,28.6%,38.1%,33.3%,37.5%和43.6%。联合组CR、PR、SD、PD、总有效率,1年生存率分别为4.3%,26.0%,34.8%,30.1%和47.5%。两者之间无统计学差异;不良反应以粒细胞减少,消化道反应,口腔黏膜炎为主,两者之间对比差异有统计学意义(P<0.05)。结论应用单药长春瑞滨一线治疗老年晚期非小细胞肺癌不仅疗效与长春瑞滨联合顺铂方案大致相同且患者有良好的耐受性,因不良反应稍多,因引起重视。

Comparing the efficacy and the toxic between vinorelbine and vinorelbine plus cisplation in the first line treatment of elder-patients with advanced non-small cell lung cancer

Objective To observe the efficacy and toxic of between vinorelbine and vinorelbine plus cispliation in first line treatment of elder-patient with advanced non-small cell lung cancer.Methods 44 elderly patients with advanced non-small cell lung cancer.21cases of them were treated with domestic vinorelbine at the dose of 25 mg/m2 on day 1,8.every 21 days.23 cases of them were treated with vinorelbine 25 mg/m2 plus cisplation 25 mg/m2.Re-evaluation was done after two cycles.Those who did not get progressed were through another two cycles of chemotherapy and all patients were followed up until disease progress or patient died.Results Domestic group CR,PR,SD,PD,response rate and 1-year survival rate was 0%,28.6%,38.1%,33.3%,37.5% and 43.6%.Relationship group CR,PR,SD,PD,response rate and 1-year survival rate was 4.3%,26.0%,34.8%,30.1% and 47.5%.There was no statistical significance in two groups.The common adverse event were neutrogena omit and catarrh.There was statistical significance only in different two groups(P<0.05).Conclusion Domestic vinorelbine is not only effective in the first line treatment of elderly patients with advanced NSCLC but also well toleration raise the patients life of quality.